PMID- 30352242
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 213
DP  - 2018 Nov 15
TI  - Hesperidin attenuates depression-related symptoms in mice with mild traumatic 
      brain injury.
PG  - 198-205
LID - S0024-3205(18)30665-9 [pii]
LID - 10.1016/j.lfs.2018.10.040 [doi]
AB  - AIMS: There is increasing evidence showing that mild traumatic brain injury 
      (mTBI) is associated with increased depression-related disorders in humans. 
      Recent studies suggest that dietary intake or supplementation of natural 
      flavonoids like hesperidin can be used for therapy of patients with brain injury 
      and depression. However, the exact mechanisms by which hesperidin indicates its 
      neuroprotective effects are not fully understood. The purpose of this study was 
      to explore the influence of hesperidin on depression-related symptoms in a mouse 
      model of mTBI, and that what mechanisms are primarily involved in the 
      antidepressant effects of this bioflavonoid. MAIN METHODS: Ten days after 
      mTBI-induction, mice received oral hesperidin treatment (50 mg/kg/14 days), then 
      animals were subjected to different depression tests including sucrose preference 
      test, forced swim test, novelty-suppressed feeding test, and tail suspension 
      test. We also measured levels of tumor necrosis factor (TNF)-alpha, 
      interleukin-(IL)-1beta, malondialdehyde (MDA), and brain-derived-neurotrophic-factor 
      (BDNF) in the hippocampus. KEY FINDINGS: Our results show that mTBI induction 
      induced depressive-like behaviors in mice by increasing inflammatory cytokines 
      (IL-1beta and TNF-alpha) and oxidative stress marker (MDA), and reducing BDNF levels in 
      the hippocampus. Interestingly, hesperidin treatment was effective to 
      significantly reduce depression-related symptoms in mTBI-induced mice. In 
      addition, hesperidin decreased the levels of IL-1beta, TNF-alpha and MDA, and increased 
      BDNF levels in the hippocampus. The major strength of our study is that four 
      behavioral tests gave similar results. SIGNIFICANCE: This study suggests that the 
      antidepressant-like effect of hesperidin may be mediated, at least in part, by 
      decreased neuroinflammation and oxidative damage, and enhanced BDNF production in 
      the hippocampus.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Kosari-Nasab, Morteza
AU  - Kosari-Nasab M
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Shokouhi, Ghaffar
AU  - Shokouhi G
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Department of Neurosurgery, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Neuroscience Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran. Electronic address: shokouhigh@yahoo.com.
FAU - Ghorbanihaghjo, Amir
AU  - Ghorbanihaghjo A
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Biotechnology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Abbasi, Mehran Mesgari
AU  - Abbasi MM
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Salari, Ali-Akbar
AU  - Salari AA
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Salari Institute of Cognitive and Behavioral Disorders (SICBD), Alborz, 
      Iran. Electronic address: aa.salari@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20181021
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antidepressive Agents)
RN  - 0 (Cytokines)
RN  - 0 (Flavonoids)
RN  - 0 (IL1B protein, mouse)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - E750O06Y6O (Hesperidin)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/pharmacology
MH  - Brain Concussion/complications/drug therapy
MH  - Cytokines/drug effects
MH  - Depression/*drug therapy
MH  - Depressive Disorder/drug therapy
MH  - Disease Models, Animal
MH  - Flavonoids/pharmacology
MH  - Hesperidin/*pharmacology
MH  - Hippocampus/metabolism
MH  - Inflammation/drug therapy
MH  - Interleukin-1beta/drug effects
MH  - Male
MH  - Malondialdehyde/pharmacology
MH  - Mice
MH  - Nerve Growth Factors/metabolism
MH  - Neuroprotective Agents/metabolism
MH  - Oxidative Stress/drug effects
MH  - Tumor Necrosis Factor-alpha/drug effects
OTO - NOTNLM
OT  - Antidepressant drugs
OT  - Cytokines
OT  - Hesperidin
OT  - Malondialdehyde
OT  - Natural flavonoids
OT  - Neurotrophins
EDAT- 2018/10/24 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/10/24 06:00
PHST- 2018/09/05 00:00 [received]
PHST- 2018/10/12 00:00 [revised]
PHST- 2018/10/19 00:00 [accepted]
PHST- 2018/10/24 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/10/24 06:00 [entrez]
AID - S0024-3205(18)30665-9 [pii]
AID - 10.1016/j.lfs.2018.10.040 [doi]
PST - ppublish
SO  - Life Sci. 2018 Nov 15;213:198-205. doi: 10.1016/j.lfs.2018.10.040. Epub 2018 Oct 
      21.